-
公开(公告)号：US20240360150A1
公开(公告)日：2024-10-31
申请号：US18683619
申请日：2022-08-22
Applicant: HANGZHOU GLUBIO PHARMACEUTICAL CO. LTD.
Inventor： Liqiang FU , Linglong KONG , Lei ZHANG , Gang LU , Yifeng XIA , Chin-Chun LU , Christine SURKA
IPC: C07D498/04 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/5383 , C07D401/04 , C07D401/14 , C07D491/107 , C07D498/14
CPC classification number: C07D498/04 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/5383 , C07D401/04 , C07D401/14 , C07D491/107 , C07D498/14
Abstract: An isoindolinone compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof can be used in the treatment of proliferative diseases. A pharmaceutical composition contains the compound or the salt thereof and a pharmaceutically acceptable carrier.
-
公开(公告)号：US20240360129A1
公开(公告)日：2024-10-31
申请号：US18763258
申请日：2024-07-03
Applicant: Ventus Therapeutics U.S., Inc.
Inventor： Stéphane DORICH , Jason BURCH , Miguel ST-ONGE , Amandine CHEFSON , Alexandre CÔTÉ , Ramsay BEVERIDGE , Stéphane CIBLAT
IPC: C07D471/04 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/5377 , C07D405/12 , C07D491/048 , C07D495/04 , C07D519/00
CPC classification number: C07D471/04 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/5377 , C07D405/12 , C07D491/048 , C07D495/04 , C07D519/00
Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
-
公开(公告)号：US20240360128A1
公开(公告)日：2024-10-31
申请号：US18763243
申请日：2024-07-03
Applicant: Ventus Therapeutics U.S., Inc.
Inventor： Stéphane DORICH , Jason BURCH , Miguel ST-ONGE , Amandine CHEFSON , Alexandre CÔTÉ
IPC: C07D471/04 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/5377 , C07D405/12 , C07D491/048 , C07D495/04 , C07D519/00
CPC classification number: C07D471/04 , A61K31/501 , A61K31/502 , A61K31/5025 , A61K31/5377 , C07D405/12 , C07D491/048 , C07D495/04 , C07D519/00
Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
-
公开(公告)号：US20240358761A1
公开(公告)日：2024-10-31
申请号：US18682798
申请日：2022-08-11
Applicant: Sana Biotechnology, Inc.
Inventor： Sonja SCHREPFER
IPC: A61K35/17 , A61K31/365 , A61K31/436 , A61K31/5377 , A61K31/573 , A61K31/675 , A61K35/30 , A61K35/36 , A61K35/39 , A61K35/44 , A61K35/55 , A61K38/13 , A61K39/00 , A61K45/06 , C07K14/705 , C12N9/22 , C12N15/11 , C12N15/86 , C12N15/90 , G01N33/68
CPC classification number: A61K35/17 , A61K31/365 , A61K31/436 , A61K31/5377 , A61K31/573 , A61K31/675 , A61K35/30 , A61K35/36 , A61K35/39 , A61K35/44 , A61K35/55 , A61K38/13 , A61K39/4611 , A61K39/4631 , A61K39/464429 , A61K45/06 , C07K14/70596 , C12N9/22 , C12N15/111 , C12N15/86 , C12N15/907 , G01N33/6854 , A61K2239/25 , A61K2239/38 , C12N2310/20 , C12N2740/15043 , G01N2333/70539 , G01N2800/24 , G01N2800/52
Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells.
-
公开(公告)号：US12128028B2
公开(公告)日：2024-10-29
申请号：US17258273
申请日：2019-07-05
Applicant: METRION BIOSCIENCES LIMITED
Inventor： Marc Rogers , Robert Kirby , Gakujun Shomi , Takuya Matsuo , Satoru Kobayashi , Junichiro Kanazawa , Nobutaka Yamaoka , Makoto Torizuka , Koichi Suzawa
IPC: A61K31/4164 , A61K31/4178 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/46 , A61K31/5377 , A61K31/55 , C07D233/28 , C07D235/02 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D409/12 , C07D471/08 , C07D491/107
CPC classification number: A61K31/4164 , A61K31/4178 , A61K31/439 , A61K31/4439 , A61K31/454 , A61K31/46 , A61K31/5377 , A61K31/55 , C07D233/28 , C07D235/02 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D409/12 , C07D471/08 , C07D491/107
Abstract: The invention relates to heterocyclic sulfonamide derivatives and their use in the treatment and prophylaxis of autoimmune, inflammatory, cardiovascular, neuronal, auditory, renal and metabolic mediated diseases, and to compositions containing said derivatives and processes for their preparation.
-
Patent Agency Ranking
公开(公告)号：US20240350505A1
公开(公告)日：2024-10-24
申请号：US18537061
申请日：2023-12-12
Applicant: Repare Therapeutics Inc.
Inventor： Michal Zimmermann , Anne Roulston , Maria Koehler
IPC: A61K31/5377 , A61K9/00 , A61K31/454 , A61K31/502 , A61K31/5025 , A61K31/541 , A61K31/55 , A61P35/00
CPC classification number: A61K31/5377 , A61K9/0053 , A61K31/454 , A61K31/502 , A61K31/5025 , A61K31/541 , A61K31/55 , A61P35/00
Abstract: Disclosed are methods of treating a cancer in a subject using an ATR inhibitor and PARP inhibitor. wherein the cancer has been previously identified as a cancer having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or as an ALT+ cancer. Also disclosed are methods of inducing cell death in an aberrant cancer cell having a loss of function of ATM, BRCA2, RNAse H2A, RNAse H2B, CDK12, or a combination thereof, or an ALT+ cancer cell, by contacting the cell with an effective amount of an ATR inhibitor and PARP inhibitor.
-
7.发明公开公开(公告)号：US20240343704A1
公开(公告)日：2024-10-17
申请号：US18288213
申请日：2022-05-02
Applicant: Ontario Institute for Cancer Research (OICR)
Inventor： Anh Chau , Methvin Isaac , Babu Joseph , Radek Laufer , Gennady Poda , Michael Prakesch , Pandiaraju Subramanian , David Uehling , Iain Watson , Brian Wilson , Tao Xin
IPC: C07D401/04 , A61K31/4725 , A61K31/496 , A61K31/4995 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5386 , A61K31/541 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/695 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/048 , C07D491/107 , C07D491/113 , C07D495/04 , C07D498/04 , C07D498/10 , C07F7/08
CPC classification number: C07D401/04 , A61K31/4725 , A61K31/496 , A61K31/4995 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5386 , A61K31/541 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/695 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/048 , C07D491/107 , C07D491/113 , C07D495/04 , C07D498/04 , C07D498/10 , C07F7/0836
Abstract: The present application relates to halo-substituted heterocyclic compounds of Formula (I): or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting HPK1, such as cancer.
-
公开(公告)号：US20240343694A1
公开(公告)日：2024-10-17
申请号：US18294422
申请日：2022-08-01
Applicant: KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY , INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Inventor： Kwangho LEE , Krishna Babu DUGGIRALA , Gil Don CHOI , Chong Hak CHAE , Myoung Eun JUNG , Yujin LEE , Byoung Chul CHO
IPC: C07D239/48 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12
CPC classification number: C07D239/48 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12
Abstract: A pyrimidine derivative, a method for preparing the pyrimidine derivative, and a pharmaceutical composition comprising the pyrimidine derivative are disclosed. Also disclosed is a method for preventing or treating cancer which includes administering the pyrimidine derivative or a composition containing the pyrimidine derivative to a subject in need of cancer treatment or prevention. The pyrimidine derivative exhibits a high inhibitory ability against EGFR mutation and HER2 mutation, and thus can be effectively used in treatment of cancer in which EGFR mutation and HER2 mutation have occurred
-
公开(公告)号：US20240342186A1
公开(公告)日：2024-10-17
申请号：US18734077
申请日：2024-06-05
Applicant: Boehringer Ingelheim International GmbH
Inventor： Annekatrin Charlotte HEIMANN , Sandra Ruth HANDSCHUH , Christoph HOENKE , Cédrickx GODBOUT , Christian GNAMM , Patrick GROSS , Marc Alexander GRUNDL , Joerg Thomas KLEY , Christian Andreas KUTTRUFF , Dirk REINART , Raphael STUBER , Theodor THEIS
IPC: A61K31/5386 , A61K31/4412 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K39/395 , A61K45/06 , A61P37/06 , C07D491/048 , C07D519/00
CPC classification number: A61K31/5386 , A61K31/4412 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61P37/06 , C07D491/048 , C07D519/00
Abstract: The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,
wherein
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1,
and prodrugs or pharmaceutically acceptable salts of these compounds
for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).-
公开(公告)号：US20240342185A1
公开(公告)日：2024-10-17
申请号：US18578875
申请日：2022-07-13
Inventor： Luke L. LAIRSON , Emily CHIN , Brett BOOKSER , David LAPOINTE
IPC: A61K31/5377 , A61K31/422 , A61K31/454 , A61K31/4545 , C07D413/04 , C07D413/06 , C07D413/14
CPC classification number: A61K31/5377 , A61K31/422 , A61K31/454 , A61K31/4545 , C07D413/04 , C07D413/06 , C07D413/14
Abstract: Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: (I) wherein R1, R2, R3, L, X, and Ar are defined in the present disclosure. The compounds are inhibitors of cyclic gmp-amp synthase (cGAS) or CGAS-related cGAMP production, and they are useful in treating or preventing inflammatory diseases or conditions in a subject.
-
-
-
-
-
-
-
-
-
Search Results
11049
records
(took 0.028 seconds)
